Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in jurkat-T cells induced by doxorubicin.
Doxorubicin remains an important part of chemotherapy regimens in the clinic and is considered an effective agent in the treatment of acute lymphoblastic leukemia (ALL). Although the cellular responses induced by doxorubicin treatment have been investigated for years, the precise mechanisms underlying its cytotoxicity and therapeutic activity remain unclear. Here we utilized mass spectrometry, together with stable isotope labeling by amino acids in cell culture (SILAC), to analyze comparatively the protein expression in Jurkat-T cells before and after treatment with a clinically relevant concentration of doxorubicin. We were able to quantify 1066 proteins in Jurkat-T cells with both forward and reverse SILAC measurements, among which 62 were with significantly altered levels of expression induced by doxorubicin treatment. These included the up-regulation of core histones, heterogeneous nuclear ribonucleoproteins, and superoxide dismutase 2 as well as the down-regulation of hydroxymethylglutaryl-CoA synthase and farnesyl diphosphate synthase. The latter two are essential enzymes for cholesterol biosynthesis. We further demonstrated that the doxorubicin-induced growth inhibition of Jurkat-T cells could be rescued by treatment with cholesterol, supporting that doxorubicin exerts its cytotoxic effect, in part, by suppressing the expression of hydroxymethylglutaryl-CoA synthase and farnesyl diphosphate synthase, thereby inhibiting the endogenous production of cholesterol. The results from the present study provide important new knowledge for gaining insights into the molecular mechanisms of action of doxorubicin.
Dong
Xiaoli
X
Department of Chemistry, University of California, Riverside, CA 92521-0403, USA.
Xiong
Lei
L
Jiang
Xinning
X
Wang
Yinsheng
Y
D049109:Cell Proliferation / Q000187:drug effects; D002784:Cholesterol / Q000096:biosynthesis / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D019169:Jurkat Cells; D053858:Metabolic Networks and Pathways / Q000187:drug effects* / Q000235:genetics; D040901:Proteomics / Q000379:methods*; D013601:T-Lymphocytes / Q000737:chemistry*
D004317:Doxorubicin; D002784:Cholesterol
J Proteome Res. 2010 Feb 5;9(2):1129-37
20050688
Annu Rev Biochem. 2003;72:743-81
12676796
Methods. 2003 Feb;29(2):124-30
12606218
Cancer Lett. 2002 Jul 8;181(1):95-107
12430184
Proc Can Cancer Conf. 1967;7:152-62
6047861
Mol Pharmacol. 1994 Apr;45(4):649-56
8183243
Proc Natl Acad Sci U S A. 1982 Jun;79(12):3823-7
6954525
Mol Cell Proteomics. 2002 May;1(5):376-86
12118079
Circ Res. 1998 Sep 7;83(5):516-22
9734474
Crit Rev Oncol Hematol. 1991;11(1):43-64
1831987
J Proteome Res. 2008 Sep;7(9):3729-36
18642942
J Lipid Res. 1988 Aug;29(8):1005-11
3183514
Prog Exp Tumor Res. 1978;22:275-316
209495
Immunopharmacol Immunotoxicol. 2010 Sep;32(3):376-86
20105085
Proteomics. 2010 Jan;10(1):99-114
20017144
Cell Growth Differ. 1994 Jul;5(7):723-33
7947387
Biochemistry. 2009 Feb 17;48(6):1256-63
19159229
Cell Death Differ. 2006 Nov;13(11):1960-7
16557274
Cancer. 1985 Jun 15;55(12):2761-5
3922612
Mol Immunol. 2007 Jul;44(15):3682-90
17524482
Electrophoresis. 1995 Jun;16(6):1034-59
7498127
Biochim Biophys Acta. 1980 Jun 5;630(1):119-30
6248123
J Biol Chem. 1990 Nov 25;265(33):20277-84
2243092
Electrophoresis. 2003 Jul;24(14):2386-404
12874874
Cancer Chemother Rep. 1969 Feb;53(1):33-7
5772652
J Biol Chem. 2000 Oct 27;275(43):33585-92
10899161
Proc Natl Acad Sci U S A. 1977 Mar;74(3):956-60
265587
Eur J Immunol. 2009 Nov;39(11):3097-109
19784949
Proteomics. 2005 Feb;5(3):796-804
15682461
Exp Cell Res. 1984 Jul;153(1):91-8
6610562
J Proteome Res. 2003 Mar-Apr;2(2):173-81
12716131
Mol Cell Proteomics. 2005 Sep;4(9):1297-310
15961381
J Proteome Res. 2009 Mar;8(3):1565-76
19199705
Nat Methods. 2008 Apr;5(4):319-22
18345006
Pharmacol Rev. 2004 Jun;56(2):185-229
15169927
Eur J Clin Pharmacol. 1985;28(2):205-12
3987800
Mol Cell Proteomics. 2004 Dec;3(12):1154-69
15385600
Med Pediatr Oncol. 2002 May;38(5):329-37
11979457
Cancer Res. 1976 Aug;36(8):2891-5
1277199
Biochim Biophys Acta. 2009 Sep;1790(9):863-8
19168116
J Proteome Res. 2007 Jun;6(6):2105-12
17472359
Science. 1984 Oct 26;226(4673):466-8
6093249
J Proteome Res. 2002 Jan-Feb;1(1):21-6
12643522
Cancer Res. 1986 Feb;46(2):617-22
2866834
Nat Biotechnol. 1999 Oct;17(10):994-9
10504701
EMBO Rep. 2002 Mar;3(3):214-8
11882539
J Proteome Res. 2010 Jan;9(1):430-43
19899826
Mol Cancer. 2010 Mar 25;9:68
20338046
Circ Res. 1999 Feb 19;84(3):257-65
10024299
Proteomics. 2004 Oct;4(10):3246-67
15378690